MET and neoplasm: In addition, Prof. Jing-Ji Yang’s team reported a case of MET D1228N mutation in a patient with EPHB4-MET fusion on crizotinib and verified that the mutant tumor may be sensitive to tivantinib, a type III MET inhibitor, in a PDX mouse model (16).